Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium
The Mechanism of Action (MoA) of a drug is generally represented as a small, non-tissue-specific repertoire of high-affinity binding targets. Yet, drug activity and polypharmacology are increasingly associated with a broad range of off-target and tissue-specific effector proteins. To address this challenge, we have implemented an efficient integrative experimental and computational framework leveraging the systematic generation and analysis of drug perturbational profiles representing >700 FDA-approved and experimental oncology drugs, in cell lines selected as high-fidelity models of 23 aggressive tumor subtypes. Protein activity-based analyses revealed highly reproducible, drug-mediated modulation of tissue-specific targets, leading to generation of a proteome-wide polypharmacology map, characterization of MoA-related drug clusters and off-target effects, and identification and experimental validation of novel, tissue-specific inhibitors of undruggable oncoproteins. The proposed framework, which is easily extended to elucidating the MoA of novel small-molecule libraries, could help support more systematic and quantitative approaches to precision oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 10. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Lucas ZhongMing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 31.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.10.08.561457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36365755X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36365755X | ||
| 003 | DE-627 | ||
| 005 | 20231226093824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.10.08.561457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM36365755X | ||
| 035 | |a (NLM)37873470 | ||
| 035 | |a (PII)2023.10.08.561457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Lucas ZhongMing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The Mechanism of Action (MoA) of a drug is generally represented as a small, non-tissue-specific repertoire of high-affinity binding targets. Yet, drug activity and polypharmacology are increasingly associated with a broad range of off-target and tissue-specific effector proteins. To address this challenge, we have implemented an efficient integrative experimental and computational framework leveraging the systematic generation and analysis of drug perturbational profiles representing >700 FDA-approved and experimental oncology drugs, in cell lines selected as high-fidelity models of 23 aggressive tumor subtypes. Protein activity-based analyses revealed highly reproducible, drug-mediated modulation of tissue-specific targets, leading to generation of a proteome-wide polypharmacology map, characterization of MoA-related drug clusters and off-target effects, and identification and experimental validation of novel, tissue-specific inhibitors of undruggable oncoproteins. The proposed framework, which is easily extended to elucidating the MoA of novel small-molecule libraries, could help support more systematic and quantitative approaches to precision oncology | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Douglass, Eugene |e verfasserin |4 aut | |
| 700 | 1 | |a Turunen, Mikko |e verfasserin |4 aut | |
| 700 | 1 | |a Pampou, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Grunn, Adina |e verfasserin |4 aut | |
| 700 | 1 | |a Realubit, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Antolin, Albert A |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Alexander L E |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniam, Prem |e verfasserin |4 aut | |
| 700 | 1 | |a Karan, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a Califano, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 10. Okt. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:10 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.10.08.561457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 10 |c 10 | ||